Oxo-oxadiazole indole derivative as well as preparation method and application thereof
A technology of oxadiazole indole derivatives and oxadiazole, which is applied in the field of new oxooxadiazole indole derivatives and their preparation, and can solve problems such as metabolic instability and AII agonism
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0067] 2-Butyl-4-chloro-1-{{1-[2-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl]-1H The preparation method of -indol-4-yl} methyl}-1H-imidazole-5-formic acid methyl ester (compound 1b) specifically comprises the following steps:
[0068] Step 1: 2-{4-[(2-Butyl-4-chloro-5-formyl-1H-imidazol-1-yl)methyl]-1H-indol 1-yl}benzonitrile (Compound VIIa- 1) Synthesis of:
[0069]
[0070] Dissolve 2-butyl 4-chloro-5-formylimidazole (10.00 g, 53.75 mmol) in N, N-dimethylformamide (100 mL), add 2-(4-chloromethylindole) benzene Nitrile (15.73 g, 59.12 mmol) and potassium carbonate (14.80 g, 107.50 mmol). The mixture was reacted at room temperature for about 2-4 h, monitored by TLC until the reaction was complete. After the temperature of the reaction solution was lowered to room temperature, it was filtered, and the filter cake was washed three times with dichloromethane (20 mL). 200 mL of dichloromethane and 200 mL of water were added to the filtrate, and the organic phase was sepa...
Embodiment 2
[0087] 2-Butyl-4-chloro-1-{{1-[2-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl]-1H -Indol-5-yl}methyl}-1H-imidazole-5-formic acid methyl ester (compound IIa) preparation method:
[0088] The synthesis method is as described in Example 1. 1 H NMR (400MHz, DMSO-d 6 )δ12.61(s, 1H), 7.92-7.78(m, 2H), 7.75-7.60(m, 2H), 7.40(d, J=3.3Hz, 1H), 7.23(d, J=1.7Hz, 1H ), 7.07(d, J=8.5Hz, 1H), 6.96-6.87(m, 1H), 6.66(d, J=3.3Hz, 1H), 5.65(s, 2H), 3.76(s, 3H), 2.67 (t, J=7.6Hz, 2H), 1.62-1.46(m, 2H), 1.33-1.23(m, 2H), 0.81(t, J=7.3Hz, 3H). 13 C NMR(101MHz,DMSO)δ159.84,159.74,156.60,152.86,137.71,135.99,135.61,133.69,131.27,130.67,129.16,129.08,129.00,128.86,121.31,121.21,118.58,117.09,110.69,104.19,52.10 , 48.70, 29.15, 26.41, 22.10, 14.04. MS (ESI) m / z: 506.2 [M+H] + .
Embodiment 3
[0090] 2-Butyl-4-chloro-1-{{1-[2-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl]-1H -Indol-4-yl}methyl}-1H-imidazole-5-formic acid (compound IIb) preparation method:
[0091] The synthesis method is as described in Example 1. 1 H NMR (400MHz, DMSO-d 6 )δ7.84(d, J=7.5Hz, 1H), 7.71-7.65(m, 1H), 7.62-7.56(m, 1H), 7.50(d, J=7.8Hz, 1H), 7.34(d, J =3.1Hz, 1H), 7.18(s, 1H), 7.05(d, J=8.4Hz, 1H), 6.87(d, J=8.5Hz, 1H), 6.64-6.51(m, 1H), 5.70(s , 2H), 2.61(t, J=7.3Hz, 2H), 1.60-1.47(m, 2H), 1.32-1.24(m, 2H), 0.81(t, J=7.3Hz, 3H). 13 C NMR(101MHz,DMSO)δ166.54,162.03,159.62,151.47,137.36,136.06,131.97,131.90,131.31,131.26,130.83,129.34,129.28,128.93,128.66,128.40,120.89,118.34,110.76,103.30,48.29 , 29.21, 26.41, 22.14, 14.08. MS (ESI) m / z: 492.1 [M+H] + .
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


